Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04078230 · ClinicalTrials.gov registry record · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
A NA study of Intrahepatic Cholangiocarcinoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.
- Recruiting
- Registry status
- NA
- Development phase
- 168
- Enrollment target
- 13
- Study locations
NCT04078230 is a NA study of Intrahepatic Cholangiocarcinoma that is actively recruiting participants, run by Second Affiliated Hospital, School of Medicine, Zhejiang University. The registered enrollment target is 168 participants, above the 126-participant average among 17 other Intrahepatic Cholangiocarcinoma trials with a reported enrollment target (33% higher). The trial reports 13 study locations across 9 states.
The verdict
NCT04078230, a NA study of Intrahepatic Cholangiocarcinoma, is actively recruiting participants, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.
- RECRUITING
- Registry status
- NA
- Development phase
- 168 participants
- Enrollment target
- 13
- Study locations
Study Summary
Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph nodes to be used for staging. The American Hepatobiliary and Pancreatic Association also recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic cholangiocarcinoma. However, some scholars have found that patients with regional lymph nodes have similar survival rates. This contradictory result has prompted more scholars to conduct clinical research to explore the necessity and standardization of lymph node dissection in intrahepatic cholangiocarcinoma.
Conditions Studied
Interventions
- PROCEDURE Extend LymphAdenectomy
Study Locations (13)
Shanghai Municipality
- Renji Hospital Affiliated to Shanghai Jiao Tong University - Shanghai
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University - Shanghai
- Zhong Shan Hospital Fudan University - Shanghai
Beijing Municipality
- China-Japan Friendship Hospital - Beijing
- Chinese PLA General Hospital - Beijing
Zhejiang
- The Second Affiliated Hospital Zhejiang University School of Medicine - Hanzhou
- Zhejiang cancer hospital - Hanzhou
Maryland
- The Johns Hopkins Hospital - Baltimore
Guangdong
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University - Guangzhou
Hunan
- Hunan Provincial People's Hospital - Changsha
Inner Mongolia
- The Affiliated Hospital of Inner Mongolia Medical University - Hohhot
Shanxi
- The First Affiliated Hospital of Xi 'an Jiaotong University - Xi’an
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04078230
The ClinicalTrials.gov registry entry for NCT04078230 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 126-participant average among 17 other Intrahepatic Cholangiocarcinoma trials with a reported enrollment target (33% higher). The listed sponsor is Second Affiliated Hospital, School of Medicine, Zhejiang University, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intrahepatic Cholangiocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Extend LymphAdenectomy is the first listed.
NCT04078230 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Shanghai Municipality, Beijing Municipality, Zhejiang.
Frequently Asked Questions
What is clinical trial NCT04078230 about?
NCT04078230 is a clinical study titled "Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma". Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph nodes to be used for staging. The American ...
What is the current status of trial NCT04078230?
This trial is currently recruiting. It is a NA study. The enrollment target is 168 participants. The study started on 2020-01-01. Estimated completion is 2027-12-31.
What conditions does trial NCT04078230 study?
This clinical trial studies the following conditions: Intrahepatic Cholangiocarcinoma.
What interventions are being tested in trial NCT04078230?
The interventions under investigation include: Extend LymphAdenectomy (PROCEDURE).
Who is sponsoring clinical trial NCT04078230?
This trial is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04078230 being conducted?
This trial has 13 study locations across Maryland, Beijing Municipality, Guangdong, Hunan, Inner Mongolia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intrahepatic Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
RECRUITING · NA
-
Infusion System for Hepatic Cancer
ACTIVE NOT RECRUITING · NA
-
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
RECRUITING
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
RECRUITING · Phase 2
-
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.